Verastem (NASDAQ:VSTM) Stock

VERASTEM INC

Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem Inc

HC Wainwright &amp; Co. analyst Sean Lee maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $10 to $14.

News

Price Target

Analyst Ratings

VSTM

HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $14

The Food and Drug Administration on Thursday granted accelerated approval to Verastem Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) Avmapki Fakzynja Co-pack, a combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">received prior systemic therapy</a>.
Efficacy was evaluated in RAMP-201 (NCT04625270), an open-label, multicenter trial that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42743560/why-is-cancer-focused-verastem-oncology-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?</a>
Patients <a target="_blank" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low" rel="noreferrer noopener">received</a> avutometinib 3.2 mg orally twice weekly (Day 1 and Day 4) and defactinib 200 mg orally twice daily, both taken for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.
The major efficacy outcome measure was overall response rate (ORR). An additional efficacy outcome measure was duration of response (DOR).
The confirmed ORR was 44%, and the DOR range was 3.3 to 31.1 months.
The recommended avutometinib dose is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.
The recommended defactinib dose is 200 mg (one tablet) taken orally twice daily for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.
In April, Verastem Oncology&nbsp;announced a private placement of approximately $24 million of shares at $7.00 per share and, in lieu of common stock, $51 million of pre-funded warrants at $6.9999 per pre-funded warrant.
Verastem expects to receive gross proceeds from the offering of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45007065/verastem-oncology-announces-75-million-private-placement" rel="noreferrer noopener">approximately $75 million</a>.
The company said it would use the proceeds to fund the potential launch of avutometinib and defactinib, as well as continued clinical research and development of product candidates, including VS-7375, working capital, and other general corporate purposes.
In April, the FDA cleared Verastem Oncology&#8217;s Investigational New Drug application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation.
The company expects to initiate a Phase 1/2a study in mid-2025 and plans for multiple expansion cohorts, including combinations, in advanced solid tumors, such as pancreatic, colorectal, and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44964117/verastem-oncology-announces-u-s-ind-clearance-of-vs-7375-oral-kras-g12d-onoff-inhibitor-enabling-p" rel="noreferrer noopener">non-small cell lung cancer</a>.
Price Action: VSTM stock was trading 3.14% higher at $6.89 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/45059756/trump-era-fda-appointees-request-new-trials-for-novavax-covid-vaccine-reportedly-delaying-approval-timeline" target="_blank" rel="noreferrer noopener">Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Health Care

Movers

General

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

Trading Ideas

Verastem Shares Resume Trade

Trading Halt: Halt status updated at 1:40:00 PM ET: Quotation Resumption: News and Resumption Times

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low</a>

'FDA Grants Accelerated Approval To The Combination Of Avutometinib And Defactinib For KRAS-Mutated Recurrent Low-grade Serous Ovarian Cancer'

Trading Halt: Halted at 11:10:03 a.m. ET - Trading Halt: Halt News Pending

WIIM

Verastem shares are trading higher after the company announced a private placement.

Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of $7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants to purchase shares of its common stock at a price of $6.9999 per pre-funded warrant. The exercise price of each pre-funded warrant will equal $0.0001 per share. Verastem expects to receive gross proceeds from the offering of approximately $75 million, before deducting placement agent fees and other offering expenses.

Verastem Oncology Announces $75M Private Placement

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$35.3K</td>
<td>866</td>
<td align="right">366</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$60.0K</td>
<td>332</td>
<td align="right">193</td>
</tr>
<tr>
<td>VSTM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$6.00</td>
<td>$25.6K</td>
<td>5.2K</td>
<td align="right">152</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$445.00</td>
<td>$119.4K</td>
<td>1</td>
<td align="right">98</td>
</tr>
<tr>
<td>PTCT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$49.00</td>
<td>$55.5K</td>
<td>2</td>
<td align="right">67</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$390.00</td>
<td>$27.3K</td>
<td>137</td>
<td align="right">46</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$135.00</td>
<td>$27.2K</td>
<td>1.7K</td>
<td align="right">26</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$700.00</td>
<td>$76.8K</td>
<td>53</td>
<td align="right">10</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$530.00</td>
<td>$41.0K</td>
<td>119</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 58 contract(s) at a $105.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $35.3K, with a price of $610.0 per contract. There were 866 open contracts at this strike prior to today, and today 366 contract(s) were bought and sold. 
• Regarding THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we observe a put option sweep with neutral sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 70 contract(s) at a $115.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $60.0K, with a price of $860.0 per contract. There were 332 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding VSTM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), we observe a call option trade with neutral sentiment. It expires in 59 day(s) on June 20, 2025. Parties traded 151 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $170.0 per contract. There were 5217 open contracts at this strike prior to today, and today 152 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option trade with bearish sentiment. It expires in 87 day(s) on July 18, 2025. Parties traded 20 contract(s) at a $445.00 strike. The total cost received by the writing party (or parties) was $119.4K, with a price of $5972.0 per contract. There were 1 open contracts at this strike prior to today, and today 98 contract(s) were bought and sold. 
• For PTCT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>), we notice a call option sweep that happens to be bearish, expiring in 241 day(s) on December 19, 2025. This event was a transfer of 50 contract(s) at a $49.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.5K, with a price of $1110.0 per contract. There were 2 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a call option sweep that happens to be bearish, expiring in 150 day(s) on September 19, 2025. This event was a transfer of 30 contract(s) at a $390.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $27.3K, with a price of $910.0 per contract. There were 137 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 59 day(s) on June 20, 2025. This event was a transfer of 12 contract(s) at a $135.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $2270.0 per contract. There were 1737 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 115 day(s) on August 15, 2025. This event was a transfer of 5 contract(s) at a $700.00 strike. The total cost received by the writing party (or parties) was $76.8K, with a price of $15360.0 per contract. There were 53 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bearish sentiment. It expires in 150 day(s) on September 19, 2025. Parties traded 4 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $41.0K, with a price of $10250.0 per contract. There were 119 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ISRG

PTCT

9 Health Care Stocks With Whale Alerts In Today's Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Joshua Dennerlein initiated coverage on MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Neutral rating and announced a price target of $585. MSCI shares closed at $549.33 on Wednesday. <a href="https://www.benzinga.com/quote/MSCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho initiated coverage on MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) with an Outperform rating and announced a price target of $12. MannKind shares closed at $4.69 on Wednesday. <a href="https://www.benzinga.com/quote/MNKD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Kelly Shi initiated coverage on Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy rating and announced a price target of $15. Verastem shares closed at $5.28 on Wednesday. <a href="https://www.benzinga.com/quote/VSTM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Tami Zakaria initiated coverage on Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) with a Neutral rating and announces Price Target of $175. Westinghouse Air Brake shares closed at $175.82 on Wednesday. <a href="https://www.benzinga.com/quote/WAB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Annabel Samimy initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy rating and announced a price target of $143. Ligand Pharmaceuticals shares closed at $103.85 on Wednesday.  <a href="https://www.benzinga.com/quote/LGND/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LGND stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="642" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-1024x642.png" alt="" class="wp-image-865923" style="width:490px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-1024x642.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-300x188.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67-768x482.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10085936/image-67.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

LGND

MNKD

MSCI

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Jefferies analyst Kelly Shi initiates coverage on Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy rating and announces Price Target of $15.

Jefferies Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $15

Mizuho analyst Mara Goldstein maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and lowers the price target from $9 to $8.

Mizuho Maintains Outperform on Verastem, Lowers Price Target to $8

Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $13 to $14.

Guggenheim Maintains Buy on Verastem, Raises Price Target to $14

HC Wainwright &amp; Co. analyst Sean Lee maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $7 to $10.

HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $10

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and lowers the price target from $16 to $14.

RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14

Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.81) by 25.93 percent. This is a 45.45 percent increase over losses of $(1.10) per share from the same period last year.

Earnings

Earnings Beats

Verastem Q4 Adj $(0.60) Beats $(0.81) Estimate

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/HNRG/earnings">a fourth-quarter sales miss.</a>
Hallador Energy reported quarterly earnings of 7 cents per share which beat the analyst consensus estimate of a loss of 13 cents per share. The company reported quarterly sales of $94.200 million which missed the analyst consensus estimate of $95.450 million.
Hallador Energy shares dipped 6.8% to $10.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares tumbled 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Ivanhoe Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IE#NYSE">IE</a>) declined 6.9% to $5.92 in pre-market trading.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares declined 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
<li>Resolute Holdings Management, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RHLD#NASDAQ">RHLD</a>) fell 4.8% to $42.05 in pre-market trading.</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) fell 4.1% to $6.75 in pre-market trading.</li>
<li>Kenon Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEN#NYSE">KEN</a>) fell 3.4% to $34.04 in pre-market trading after gaining 3% on Monday.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) fell 3.3% to $2.32 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1.6% to $234.30 in pre-market trading. Tesla shares fell 4.8% on Monday after Mizuho cut its price target on the stock from $515 to $430. &nbsp;</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

AKBA

ARLO

HNRG

RHLD

TSLA

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Shares of Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial results and <a href="https://www.benzinga.com/quote/HROW/earnings">issued 2025 revenue guidance</a>.
Harrow shares jumped 23.1% to $28.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 45.7% to $26.96 in pre-market trading after jumping over 46% on Monday.</li>
<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) rose 30.4% to $0.7985 in pre-market trading. Bon Natural Life shares dipped 57% on Monday after the company announced the pricing of a $12 million offering of 8,333,332 shares at $1.44/share.</li>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) gained 19.2% to $0.4774 in pre-market trading following a 10% surge on Monday.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) gained 17.8% to $1.39 in pre-market trading after jumping 7% on Monday.</li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) gained 15% to $1.46 in pre-market after gaining 4% on Monday.</li>
<li>Key Tronic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) gained 14.2% to $3.05 in pre-market trading.</li>
<li>FinVolution Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) rose 11% to $10.12 following fourth-quarter results.</li>
<li>X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) rose 9.3% to $14.10 in pre-market trading after gaining 3% on Monday.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 6.3% to $4.73 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 40.3% to $0.5250 in pre-market trading.</li>
<li>Bakkt Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) fell 29.4% to $9.05 in pre-market trading after gaining 7% on Monday.</li>
<li>Hyperfine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) dipped 25.8% to $0.95 in pre-market trading following fourth-quarter results.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) declined 24.3% to $0.1280 in pre-market trading.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) fell 24.1% to $0.0802 in pre-market trading after dipping over 6% on Monday.</li>
<li>AirNet Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) shares tumbled 18.5% to $1.31 in pre-market trading. AirNet Technology shares jumped 98% on Monday after the company announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) shares fell 13.1% to $0.2469 in pre-market trading. CEL-SCI announced the pricing of $2.56 million best-efforts offering of 16 million shares of common stock.</li>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares dipped 9.3% to $10.01 in pre-market trading after gaining 4% on Monday.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) fell 6.8% to $10.70 in today's pre-market trading following a fourth-quarter sales miss.</li>
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) fell 6% to $6.80 in pre-market trading after gaining 4% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

AGMH

ANTE

ARBE

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HROW

HYPR

KTCC

VRPX

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket

B. Riley Securities analyst Kalpit Patel maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $7 to $9.

B. Riley Securities Maintains Buy on Verastem, Raises Price Target to $9

Guggenheim analyst Michael Schmidt reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) from Buy to Buy.

Reiteration

Guggenheim Reiterates Buy on Verastemto Buy

Press Releases

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Small Cap

Opinion

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology to Present at Upcoming Investor Conferences

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

Comments

Verastem

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL